PONTE
VEDRA, Fla., Jan. 31,
2024 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in
anticoagulation (blood thinning) therapy, cited today a recent
peer-reviewed article in the Journal of the American College of
Cardiology (JACC) titled, "When Direct Oral Anticoagulants Should
Not Be Standard Treatment" by Antoine
Bejjani, MD, et.al. The article examines the numerous
medical conditions where direct oral anticoagulants (DOACs), such
as Eliquis, Xarelto, Pradaxa, and Savaysa, should not be
prescribed.
Consistent with the evolving evidence documenting the need for
VKA-based anticoagulant therapy, while simultaneously recognizing
the deficiencies of the available VKA anticoagulants (such as
warfarin), this latest peer-reviewed journal publication
highlights:
- For most patients, DOACs are preferred over existing Vitamin K
Antagonists [warfarin] for stroke prevention in atrial fibrillation
(AFib) and venous thromboembolism treatment.
- However, randomized controlled trials indicate that DOACs may
not be as efficacious or as safe in conditions such as mechanical
heart valves, thrombotic antiphospholipid syndrome (APS), and AFib
associated with end-stage kidney disease (ESKD).
- Their [DOACs] efficacy is uncertain for conditions such as left
ventricular thrombus, and for patients with AFib or venous
thrombosis who have ESKD.
"This expert review provides an assessment of the available
evidence regarding DOACs, detailing not only when they have
demonstrated efficacy and safety, but also when the DOACs have
failed and therefore should not be the standard of care," commented
Quang Pham, Founder, Chairman and
Chief Executive Officer of Cadrenal Therapeutics. "These critical
gaps in anticoagulation therapy, such as for patients with left
ventricular assist devices (LVADs), thrombotic APS, and those with
AFib and ESKD, highlight and support the need for the
advancement of our tecarfarin development program to serve these
patients."
Further information on the article is available at
https://www.jacc.org/doi/epdf/10.1016/j.jacc.2023.10.038.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin for unmet
needs in anticoagulation therapy. Tecarfarin is a
late-stage novel oral and reversible anticoagulant (blood thinner)
to prevent heart attacks, strokes, and deaths due to blood clots in
patients with certain medical conditions. Tecarfarin
has orphan drug and fast track designations from the FDA for
the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end-stage kidney disease
(ESKD) and atrial fibrillation
(AFib). Cadrenal is also pursuing
additional regulatory strategies for unmet needs in anticoagulation
therapy for patients with left ventricular assist devices
(LVADs) and those with thrombotic
antiphospholipid syndrome
(APS). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist
(warfarin). Tecarfarin has been evaluated
in eleven (11) human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated
in both healthy adult subjects and patients with chronic kidney
disease. For more information, please visit:
www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding the critical gaps in anticoagulation therapy, such as for
patients with left ventricular assist devices (LVADs), thrombotic
APS, and those with AFib and ESKD, highlighting and supporting
the need for the advancement of our tecarfarin development program
to serve these patients.The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
ability to advance tecarfarin with patients with left ventricular
assist devices (LVADs), thrombotic APS, and those with AFib and
ESKD and the other risk factors described in the Company's
Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's subsequent
filings with the SEC, including subsequent periodic reports on
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any
forward-looking statements contained in this press release speak
only as of the date hereof and, except as required by federal
securities laws, the Company specifically disclaims any obligation
to update any forward-looking statement, whether as a result of new
information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing
Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-highlights-publication-of-peer-reviewed-article-supporting-need-for-new-anticoagulation-therapy-for-patients-with-certain-medical-conditions-302048797.html
SOURCE Cadrenal Therapeutics, Inc.